Recent Company News

• 09:53 AM ET Oct 06, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (239 total)

• 11:40 AM ET Sep 17, 2025
  

  Transcript Intelligence: Compass Pathways at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

• 06:32 AM ET Sep 02, 2025
  

  Compass Pathways notes publication of results from Phase 2 study of COMP360 psilocybin for PTSD ($4.42, 0.00)

• 06:32 AM ET Jul 31, 2025
  

  Compass Pathways reports Q2 EPS ($0.41) vs FactSet ($0.43) [11 est, ($0.56)-(0.34)] ($3.94, 0.00)

• 08:55 AM ET Jul 07, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 05:05 PM ET Jun 23, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 07:29 PM ET Jun 27, 2025
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 10:05 AM ET Jun 23, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (89 total)

• 09:17 AM ET Jun 23, 2025
  

  StreetAccount Summary - US Pre-market trading update